Aims: We conducted this study to examine the role of trigger point injections in females with chronic pelvic pain (CPP) of at least 6 months duration and speci¢c levator ani trigger points. Methods: This prospective study included 18 consecutive female patients with CPP and speci¢c palpable levator ani trigger points. Pain was evaluated before and after trigger point injection on a Visual Analog Scale (VAS). Patient global satisfaction (PGS) and cure rates (PGC) were also measured by aVAS on a scale of 0^100%. The trigger points were identi¢ed manually by intravaginal palpation of the levator ani bilaterally. A mixture of 10 cc of 0.25% bupivacaine, 10 cc of 2% lidocaine and 1 cc (40 mg) of triamcinolone was used for injection of 5 cc per trigger point. A 5.5 00 Iowa trumpet pudendal needle guide was used for injection. All but one injection were performed in the o⁄ce setting without sedation. Pelvic £oor muscle exercises were taught for use after injection. Success was de¢ned as a decrease in pain as measured by a VAS of 50% or more, as well as PGS and PGC scores of 60% or greater. There was a mean follow up of 3 months after trigger point injection.Results: Thirteen of 18 women improved with the ¢rst trigger point injection resulting in a comprehensive success rate of 72%. Six (33%) of 18 women were completely pain free. Conclusion: In the management of CPP, a non-surgical o⁄ce-based therapy such as trigger point injections can be e¡ective in selected patients. Neurourol. Urodynam. 26: 59^62, 2007. ß 2006